Year |
Citation |
Score |
2024 |
Annapragada AV, Niknafs N, White JR, Bruhm DC, Cherry C, Medina JE, Adleff V, Hruban C, Mathios D, Foda ZH, Phallen J, Scharpf RB, Velculescu VE. Genome-wide repeat landscapes in cancer and cell-free DNA. Science Translational Medicine. 16: eadj9283. PMID 38478628 DOI: 10.1126/scitranslmed.adj9283 |
0.47 |
|
2023 |
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, ... ... Velculescu VE, et al. Dual blockade of BRD4 and ATR/WEE1 pathways exploits loss in clear cell ovarian cancer. Research Square. PMID 37841875 DOI: 10.21203/rs.3.rs-3314138/v1 |
0.355 |
|
2023 |
Medina JE, Dracopoli NC, Bach PB, Lau A, Scharpf RB, Meijer GA, Andersen CL, Velculescu VE. Cell-free DNA approaches for cancer early detection and interception. Journal For Immunotherapy of Cancer. 11. PMID 37696619 DOI: 10.1136/jitc-2022-006013 |
0.37 |
|
2023 |
Bruhm DC, Mathios D, Foda ZH, Annapragada AV, Medina JE, Adleff V, Chiao EJ, Ferreira L, Cristiano S, White JR, Mazzilli SA, Billatos E, Spira A, Zaidi AH, Mueller J, ... ... Velculescu VE, et al. Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer. Nature Genetics. PMID 37500728 DOI: 10.1038/s41588-023-01446-3 |
0.487 |
|
2023 |
Topper MJ, Anagnostou V, Marrone KA, Velculescu VE, Jones PA, Brahmer JR, Baylin SB, Hostetter GH. Derivation of CD8 T cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis. Iscience. 26: 107095. PMID 37456850 DOI: 10.1016/j.isci.2023.107095 |
0.31 |
|
2023 |
Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, ... ... Velculescu VE, et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics. PMID 37024582 DOI: 10.1038/s41588-023-01355-5 |
0.318 |
|
2023 |
Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, ... ... Velculescu VE, et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nature Medicine. PMID 36702947 DOI: 10.1038/s41591-022-02163-w |
0.455 |
|
2022 |
van 't Erve I, Medina JE, Leal A, Papp E, Phallen J, Adleff V, Chiao EJ, Arun AS, Bolhuis K, Simmons JK, Karandikar A, Valkenburg KC, Sausen M, Angiuoli SV, Scharpf RB, ... ... Velculescu VE, et al. Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36534496 DOI: 10.1158/1078-0432.CCR-22-2538 |
0.429 |
|
2022 |
Foda ZH, Annapragada AV, Boyapati K, Bruhm DC, Vulpescu NA, Medina JE, Mathios D, Cristiano S, Niknafs N, Luu HT, Goggins MG, Anders RA, Sun J, Mehta SH, Thomas DL, ... ... Velculescu VE, et al. Detecting liver cancer using cell-free DNA fragmentomes. Cancer Discovery. PMID 36399356 DOI: 10.1158/2159-8290.CD-22-0659 |
0.319 |
|
2022 |
Anagnostou V, Landon BV, Medina JE, Forde P, Velculescu VE. Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Science Translational Medicine. 14: eabo3958. PMID 36350985 DOI: 10.1126/scitranslmed.abo3958 |
0.387 |
|
2022 |
Botsis T, Murray J, Leal A, Palsgrove D, Wang W, White JR, Velculescu VE, Anagnostou V. Natural Language Processing Approaches for Retrieval of Clinically Relevant Genomic Information in Cancer. Studies in Health Technology and Informatics. 295: 350-353. PMID 35773881 DOI: 10.3233/SHTI220735 |
0.351 |
|
2022 |
Keefer LA, White JR, Wood DE, Gerding KMR, Valkenburg KC, Riley D, Gault C, Papp E, Vollmer CM, Greer A, Hernandez J, McGregor PM, Zingone A, Ryan BM, Deak K, ... ... Velculescu VE, et al. Automated next-generation profiling of genomic alterations in human cancers. Nature Communications. 13: 2830. PMID 35595835 DOI: 10.1038/s41467-022-30380-x |
0.484 |
|
2021 |
van 't Erve I, Wesdorp NJ, Medina JE, Ferreira L, Leal A, Huiskens J, Bolhuis K, van Waesberghe JTM, Swijnenburg RJ, van den Broek D, Velculescu VE, Kazemier G, Punt CJA, Meijer GA, Fijneman RJA. A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. Jco Precision Oncology. 5. PMID 34820593 DOI: 10.1200/PO.21.00223 |
0.345 |
|
2021 |
Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, Lanis M, Belcaid Z, Smith KN, Balan A, White JR, ... ... Velculescu VE, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature Medicine. PMID 34750557 DOI: 10.1038/s41591-021-01541-0 |
0.344 |
|
2021 |
Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, Bruhm DC, Niknafs N, Ferreira L, Adleff V, Chiao JY, Leal A, Noe M, White JR, Arun AS, ... ... Velculescu VE, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nature Communications. 12: 5060. PMID 34417454 DOI: 10.1038/s41467-021-24994-w |
0.357 |
|
2021 |
Mathios D, Johansen JS, Cristiano S, Medina J, Phallen J, Richter Larsen K, Bruhm D, Niknafs N, Nielsen HJ, Meijer GA, Andersen CL, Bojesen SE, Scharpf R, Velculescu VE. Early detection of lung cancer using cfDNA fragmentation. Journal of Clinical Oncology. 39: 8519-8519. DOI: 10.1200/JCO.2021.39.15_SUPPL.8519 |
0.37 |
|
2021 |
Belcaid Z, Balan A, Cherry C, Lanis M, Marrone K, Levy BP, Schneider H, Rodavia H, Jobe BA, Thompson E, Velculescu VE, Battafarano RJ, Yang S, Broderick S, Ha JS, et al. Immunogenomic features of pathologic response to neoadjuvant immune checkpoint blockade in esophageal cancer. Journal of Clinical Oncology. 39: 4042-4042. DOI: 10.1200/JCO.2021.39.15_SUPPL.4042 |
0.411 |
|
2021 |
Carey J, Jones S, Leal A, Chesnick B, Butler D, Rongione M, Scharpf RB, Johansen JS, Velculescu VE, Dracopoli NC. Genome-wide cfDNA fragmentation in patients with cancer and other diseases. Journal of Clinical Oncology. 39: 3136-3136. DOI: 10.1200/JCO.2021.39.15_SUPPL.3136 |
0.423 |
|
2021 |
Carey J, Chesnick B, Butler D, Rongione M, Parmigiani G, Velculescu VE, Dracopoli NC, Scharpf RB. Modeling cell-free DNA fragment size densities for non-invasive detection of cancer. Journal of Clinical Oncology. 39: 3058-3058. DOI: 10.1200/JCO.2021.39.15_SUPPL.3058 |
0.365 |
|
2020 |
Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW, Stein J, Tsai HL, Wang H, Belcaid Z, Murray J, Balan A, Ferreira L, Ross-Macdonald P, Wind-Rotolo M, ... ... Velculescu VE, et al. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Reports. Medicine. 1: 100139. PMID 33294860 DOI: 10.1016/j.xcrm.2020.100139 |
0.309 |
|
2020 |
Anagnostou V, Niknafs N, Marrone K, Bruhm DC, White JR, Naidoo J, Hummelink K, Monkhorst K, Lalezari F, Lanis M, Rosner S, Reuss JE, Smith KN, Adleff V, Rodgers K, ... ... Velculescu VE, et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature Cancer. 1: 99-111. PMID 32984843 DOI: 10.1038/s43018-019-0008-8 |
0.436 |
|
2020 |
Erve IV', Greuter MJE, Bolhuis K, Vessies DCL, Leal A, Vink GR, van den Broek D, Velculescu VE, Punt CJA, Meijer GA, Coupé VMH, Fijneman RJA. Diagnostic strategies towards clinical implementation of liquid biopsy RAS/BRAF circulating tumor DNA analyses in patients with metastatic colorectal cancer. The Journal of Molecular Diagnostics : Jmd. PMID 32961317 DOI: 10.1016/J.Jmoldx.2020.09.002 |
0.353 |
|
2020 |
Schraa SJ, van Rooijen KL, van der Kruijssen DEW, Rubio Alarcón C, Phallen J, Sausen M, Simmons J, Coupé VMH, van Grevenstein WMU, Elias S, Verkooijen HM, Laclé MM, Bosch LJW, van den Broek D, Meijer GA, ... Velculescu VE, et al. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. Bmc Cancer. 20: 790. PMID 32819390 DOI: 10.1186/S12885-020-07252-Y |
0.304 |
|
2020 |
Noë M, Niknafs N, Fischer CG, Hackeng WM, Beleva Guthrie V, Hosoda W, Debeljak M, Papp E, Adleff V, White JR, Luchini C, Pea A, Scarpa A, Butturini G, Zamboni G, ... ... Velculescu VE, et al. Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nature Communications. 11: 4085. PMID 32796935 DOI: 10.1038/S41467-020-17917-8 |
0.374 |
|
2020 |
Leal A, van Grieken NCT, Palsgrove DN, Phallen J, Medina JE, Hruban C, Broeckaert MAM, Anagnostou V, Adleff V, Bruhm DC, Canzoniero JV, Fiksel J, Nordsmark M, Warmerdam FARM, Verheul HMW, ... ... Velculescu VE, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nature Communications. 11: 525. PMID 31988276 DOI: 10.1038/S41467-020-14310-3 |
0.346 |
|
2020 |
Anagnostou V, Bruhm DC, Niknafs N, White JR, Sidhom J, Stein JE, Tsai H, Wang H, Belcaid Z, Murray JC, Ross-Macdonald PB, Wind-Rotolo M, Baras AS, Taube JM, Scharpf RB, ... ... Velculescu VE, et al. Integrative tumor and immune cell multi-omic analyses to predict melanoma response to immune checkpoint blockade. Journal of Clinical Oncology. 38: 10009-10009. DOI: 10.1200/jco.2020.38.15_suppl.10009 |
0.314 |
|
2020 |
Arniella M, Ravi A, Stewart C, Freeman S, Awad M, Forde P, Anagnostou V, Henick B, Riess J, Gibbons D, Pennell N, Velcheti V, Leshchiner I, Kim J, Digumarthy S, ... ... Velculescu V, et al. Abstract 5902: Integrative genomic analysis of checkpoint blockade in lung cancer: A multi-institution SU2C collaborative Cancer Research. 80: 5902-5902. DOI: 10.1158/1538-7445.Am2020-5902 |
0.491 |
|
2020 |
Alarcón CR, Kruijssen DEvd, Meiqari L, Bosch LJ, Simmons JK, Velculescu VE, Broek Dvd, Punt CJ, Coupé VM, Koopman M, Meijer GA, Vink GR, Fijneman RJ. Abstract 3096: Liquid biopsy cell-free circulating tumor DNA as prognostic biomarker for stage III colon cancer patients Clinical Trials. DOI: 10.1158/1538-7445.Am2020-3096 |
0.365 |
|
2019 |
Georgiadis A, Durham JN, Keefer LA, Bartlett BR, Zielonka M, Murphy D, White JR, Lu S, Verner EL, Ruan F, Riley D, Anders RA, Gedvilaite E, Angiuoli S, Jones S, ... Velculescu VE, et al. Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31506389 DOI: 10.1158/1078-0432.Ccr-19-1372 |
0.438 |
|
2019 |
Mathios D, Hwang T, Xia Y, Phallen J, Rui Y, See AP, Maxwell R, Belcaid Z, Casaos J, Burger PC, McDonald KL, Gallia GL, Cope L, Kai M, Brem H, ... ... Velculescu VE, et al. Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types. International Journal of Cancer. PMID 31373686 DOI: 10.1002/Ijc.32587 |
0.366 |
|
2019 |
Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, ... ... Velculescu VE, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. PMID 31142840 DOI: 10.1038/S41586-019-1272-6 |
0.436 |
|
2019 |
Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, ... ... Velculescu VE, et al. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31142500 DOI: 10.1158/1078-0432.Ccr-19-0197 |
0.321 |
|
2019 |
Leal A, Cristiano S, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Palsgrove DN, Niknafs N, Anagnostou V, Forde PM, Brahmer JR, Fijneman R, Johansen JS, ... ... Velculescu VE, et al. Genome-wide cell-free DNA fragmentation profiling for early cancer detection. Journal of Clinical Oncology. 37: 3018-3018. DOI: 10.1200/Jco.2019.37.15_Suppl.3018 |
0.411 |
|
2019 |
Kinose Y, Hallberg D, Mills G, Ince T, Velculescu V, Simpkins F, Drapkin R. Abstract GMM-036: COMPREHENSIVE GENOMIC, PROTEOMIC, AND EXPERIMENTAL CHARACTERIZATION OF OVARIAN CLEAR CELL CARCINOMA CELL LINES FOR IMPROVED DRUG DEVELOPMENT Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Gmm-036 |
0.467 |
|
2019 |
Erve Iv', Leal A, Bolhuis K, Phallen J, Grieken Nv, Coupé V, Broeks A, Broek Dvd, Velculescu V, Punt C, Meijer G, Fijneman R. Abstract 3977: Clinical validation of cell-free circulating tumor DNA to detect therapy resistance and disease progression in metastatic colorectal cancer patients Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3977 |
0.482 |
|
2019 |
Caushi JX, Ji Z, Zhang J, Asmar ME, Anagnostou V, Cottrell TR, Chan HY, Guo H, Merghoub T, Wolchok JD, Naidoo J, Marrone KA, Chaft JE, Hellmann MD, Gabrielson E, ... ... Velculescu VE, et al. Abstract 4041: Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC Cancer Research. 79: 4041-4041. DOI: 10.1158/1538-7445.Am2019-4041 |
0.308 |
|
2019 |
Kinose Y, Hallberg D, Doberstein K, Mills G, Ince T, Velculescu V, Simpkins F, Drapkin R. Abstract 1065: Comprehensive molecular and experimental characterization of ovarian clear cell carcinoma cell lines forin vivodrug development Cancer Research. 79: 1065-1065. DOI: 10.1158/1538-7445.Am2019-1065 |
0.431 |
|
2018 |
Campos MP, Cohen M, Von Euw E, Velculescu V, Kujak JL, Conklin D, Hallberg D, Slamon DJ, Elvin J, Konecny GE. Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition. Jco Precision Oncology. 2. PMID 31799491 DOI: 10.1200/PO.18.00025 |
0.343 |
|
2018 |
Phallen J, Leal A, Woodward BD, Forde PM, Naidoo J, Marrone KA, Brahmer JR, Fiksel J, Medina JE, Cristiano S, Palsgrove DN, Gocke CD, Bruhm DC, Keshavarzian P, Adleff V, ... ... Velculescu VE, et al. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. Cancer Research. PMID 30573519 DOI: 10.1158/0008-5472.CAN-18-1082 |
0.32 |
|
2018 |
Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Palsgrove D, Conklin D, Kinose Y, White JR, Press MF, Drapkin R, Easwaran H, Baylin SB, ... ... Velculescu VE, et al. Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports. 25: 2617-2633. PMID 30485824 DOI: 10.1016/J.Celrep.2018.10.096 |
0.443 |
|
2018 |
Wood DE, White JR, Georgiadis A, Van Emburgh B, Parpart-Li S, Mitchell J, Anagnostou V, Niknafs N, Karchin R, Papp E, McCord C, LoVerso P, Riley D, Diaz LA, Jones S, ... ... Velculescu VE, et al. A machine learning approach for somatic mutation discovery. Science Translational Medicine. 10. PMID 30185652 DOI: 10.1126/Scitranslmed.Aar7939 |
0.448 |
|
2018 |
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, ... ... Velculescu VE, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England Journal of Medicine. PMID 29658848 DOI: 10.1056/Nejmoa1716078 |
0.323 |
|
2018 |
Nichol D, Jones S, Angiouli SV, Keefer L, Nesselbush M, Sengamalay N, White J, Simmons J, Diaz LA, Velculescu VE, Sausen M. Pan-Cancer assessment of tumor mutational burden using a comprehensive genomic profiling assay. Journal of Clinical Oncology. 36: 157-157. DOI: 10.1200/JCO.2018.36.5_SUPPL.157 |
0.442 |
|
2018 |
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, ... ... Velculescu VE, et al. Abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct079 |
0.3 |
|
2018 |
Anagnostou V, Forde P, Naidoo J, Marrone K, Adleff V, White J, Phallen J, Leal A, Hruban C, Sivakumar A, Verde F, Karchin R, Brahmer J, Velculescu V. Abstract 3668: ctDNA and TCR dynamics predict response toimmune checkpoint blockade in non-small cell lung cancer Cancer Research. 78: 3668-3668. DOI: 10.1158/1538-7445.Am2018-3668 |
0.486 |
|
2018 |
Wood D, White J, Georgiadis A, Emburgh BV, Parpart-Li S, Mitchell J, Anagnostou V, Niknafs N, Karchin R, Papp E, McCord C, Loverso P, Riley D, Diaz LA, Jones S, ... ... Velculescu VE, et al. Abstract 3271: A machine learning approach for somatic mutation discovery Cancer Research. 78: 3271-3271. DOI: 10.1158/1538-7445.Am2018-3271 |
0.412 |
|
2018 |
Nesselbush M, Jones S, Keefer L, Sengamalay N, Velculescu V, Diaz L, Sausen M, Angiuoli S. Abstract A027: Analytic validation of a pan-cancer tumor mutational burden assay Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A027 |
0.54 |
|
2017 |
Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, ... ... Velculescu VE, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications. 8: 1093. PMID 29061967 DOI: 10.1038/S41467-017-00962-1 |
0.341 |
|
2017 |
Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, ... ... Velculescu VE, et al. Direct detection of early-stage cancers using circulating tumor DNA. Science Translational Medicine. 9. PMID 28814544 DOI: 10.1126/Scitranslmed.Aan2415 |
0.528 |
|
2017 |
Barrett MT, Deiotte R, Lenkiewicz E, Malasi S, Holley T, Evers L, Posner RG, Jones T, Han H, Sausen M, Velculescu VE, Drebin J, O'Dwyer P, Jameson G, Ramanathan RK, et al. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. British Journal of Cancer. PMID 28720843 DOI: 10.1038/Bjc.2017.209 |
0.366 |
|
2017 |
Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, ... ... Velculescu VE, et al. Precancer Atlas to Drive Precision Prevention Trials. Cancer Research. 77: 1510-1541. PMID 28373404 DOI: 10.1158/0008-5472.Can-16-2346 |
0.388 |
|
2017 |
Yeung KT, More S, Woodward B, Velculescu V, Husain H. Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer. Molecular Diagnosis & Therapy. PMID 28337711 DOI: 10.1007/S40291-017-0260-5 |
0.391 |
|
2017 |
Chaft JE, Forde PM, Smith KN, Anagnostou V, Cottrell T, Taube JM, Rekhtman N, Merghoub T, Jones DR, Hellmann MD, Yang SC, Broderick S, Rusch VW, Velculescu VE, Topalian SL, et al. Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers. Journal of Clinical Oncology. 35: 8508-8508. DOI: 10.1200/JCO.2017.35.15_SUPPL.8508 |
0.331 |
|
2017 |
Phallen JA, Sausen M, Adleff V, Leal A, Fiksel J, Hruban C, Speir S, Papp E, Anagnostou V, Orntoft MW, Reinert T, Woodward BD, Murphy D, Parpart-Li S, Riley D, ... ... Velculescu VE, et al. Abstract LB-246: Detection of circulating tumor DNA in early stage cancers Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-246 |
0.353 |
|
2017 |
Novak M, Angiuoli S, Diaz LA, Georgiadis A, Jones S, Loverso PR, Parpart-Li S, Sevdali M, Velculescu VE, Verner EL, White J, Zhang T, Sausen M. Abstract 604: Accurate identification and prioritization of candidate neoantigens from integrated cancer exome and transcriptome sequencing of FFPE samples Cancer Research. 77: 604-604. DOI: 10.1158/1538-7445.Am2017-604 |
0.41 |
|
2016 |
Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, ... ... Velculescu VE, et al. Evolution of Neoantigen Landscape During Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discovery. PMID 28031159 DOI: 10.1158/2159-8290.Cd-16-0828 |
0.329 |
|
2016 |
Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R, Georgiadis A, Phallen J, Brahmer JR, Azad NA, Browner I, Laheru DA, Velculescu VE, Sausen M, Diaz LA. The effect of preservative and temperature on the analysis of circulating tumor DNA. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27827317 DOI: 10.1158/1078-0432.CCR-16-1691 |
0.314 |
|
2016 |
Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, ... ... Velculescu VE, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27573169 DOI: 10.1158/1078-0432.Ccr-16-1237 |
0.328 |
|
2016 |
Hao Y, Samuels Y, Li Q, Krokowski D, Guan BJ, Wang C, Jin Z, Dong B, Cao B, Feng X, Xiang M, Xu C, Fink S, Meropol NJ, Xu Y, ... ... Velculescu VE, et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nature Communications. 7: 11971. PMID 27321283 DOI: 10.1038/Ncomms11971 |
0.351 |
|
2016 |
Hamm CA, Moran D, Rao K, Trusk PB, Pry K, Sausen M, Jones S, Velculescu VE, Cristofanilli M, Bacus S. Genomic and immunological tumor profiling identifies targetable pathways and extensive CD8+/PDL1+ immune infiltration in inflammatory breast cancer tumors. Molecular Cancer Therapeutics. PMID 27196778 DOI: 10.1158/1535-7163.MCT-15-0353 |
0.427 |
|
2016 |
Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... Velculescu V, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6 |
0.357 |
|
2016 |
White J, Simmons J, Angiuoli S, Sausen M, Jones S, Kann L, Shukla M, Sevdali M, Velculescu V, Diaz L, Zhang T. Abstract A039: Accurate identification and prioritization of candidate neoantigens from cancer exome sequencing Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A039 |
0.539 |
|
2016 |
White J, Angiuoli S, Sausen M, Jones S, Kann L, Shukla M, Sevdali M, Velculescu V, Diaz L, Zhang T. Abstract 528: Identify and prioritize candidate neoantigens from cancer exome sequencing with unmatched accuracy Cancer Research. 76: 528-528. DOI: 10.1158/1538-7445.Am2016-528 |
0.553 |
|
2016 |
Parpart-Li ST, Bartlett B, Popoli M, Adleff V, Brahmer J, Azad N, Bonerigo S, Browner I, Ryan A, Velculescu V, Sausen M, Diaz LA. Abstract 3957: Optimized plasma collection procedures for liquid biopsy analyses in cancer Cancer Research. 76: 3957-3957. DOI: 10.1158/1538-7445.Am2016-3957 |
0.453 |
|
2016 |
Vaz MP, Hwang SY, Patil A, Phallen J, Murphy L, Zahnow CA, Velculescu VE, Easwaran H, Baylin SB. Abstract 2773: Chronic cigarette smoke exposure of bronchial epithelial cells induces progressive epigenomic changes leading to transformation Cancer Research. 76: 2773-2773. DOI: 10.1158/1538-7445.Am2016-2773 |
0.339 |
|
2015 |
Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, ... ... Velculescu VE, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. PMID 26416732 DOI: 10.1038/Nature14969 |
0.345 |
|
2015 |
Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, Drapkin R. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecologic Oncology. 139: 97-103. PMID 26321251 DOI: 10.1016/J.Ygyno.2015.08.017 |
0.351 |
|
2015 |
Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O'Dwyer PJ, Allen PJ, ... ... Velculescu VE, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications. 6: 7686. PMID 26154128 DOI: 10.1038/Ncomms8686 |
0.73 |
|
2015 |
Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp E, Galens KG, Murphy D, Zhang T, Kann L, Sausen M, ... ... Velculescu VE, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Science Translational Medicine. 7: 283ra53. PMID 25877891 DOI: 10.1200/Jco.2015.33.15_Suppl.1529 |
0.576 |
|
2015 |
Izumchenko E, Sun K, Jones S, Brait M, Agrawal N, Koch W, McCord CL, Riley DR, Angiuoli SV, Velculescu VE, Jiang WW, Sidransky D. Notch1 mutations are drivers of oral tumorigenesis. Cancer Prevention Research (Philadelphia, Pa.). 8: 277-86. PMID 25406187 DOI: 10.1158/1940-6207.CAPR-14-0257 |
0.316 |
|
2015 |
Wang JS, Sausen M, Parpart-Li S, Murphy DM, Velculescu VE, Wood LD, Solt-Linville S, Sugar E, Bartlett B, Blair C, Dauses T, Jaffee EM, Hruban RH, Laheru D, Diaz LA. Circulating tumor DNA (ctDNA) as a prognostic marker for recurrence in resected pancreas cancer. Journal of Clinical Oncology. 33: 11025-11025. DOI: 10.1200/Jco.2015.33.15_Suppl.11025 |
0.443 |
|
2015 |
Michailidi C, Noordhuis M, Hadar T, Marchioni L, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu V, Sidransky D, Guerrero-Preston R. Abstract B1-62: Bumphunting analysis identifies PAX5 promoter methylation and p53 somatic mutations in genomic instability pathways linked to very poor survival in head and neck cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-B1-62 |
0.464 |
|
2015 |
Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Lytle K, Parpart-Li S, Murphy D, Barrett MT, Linehan DC, Maitra A, Hruban R, Hoff DDV, Johansen JS, Diaz LA, ... ... Velculescu VE, et al. Abstract 619: Identification of clinically actionable genomic alterations in the tumor and circulation of pancreatic cancer patients Cancer Research. 75: 619-619. DOI: 10.1158/1538-7445.Am2015-619 |
0.795 |
|
2015 |
Jones S, Sausen M, Anagnostou V, Angiuoli SV, Chesnick B, Galens K, Kadan M, Kann L, Lytle K, Murphy D, Nesselbush M, Papp E, Parpart-Li S, Riley D, Shukla M, ... ... Velculescu VE, et al. Abstract 3894: The importance of matched tumor and normal DNA for somatic mutation discovery and clinical interpretation Cancer Research. 75: 3894-3894. DOI: 10.1158/1538-7445.Am2015-3894 |
0.511 |
|
2015 |
Moran D, Hamm CA, Rao K, Bacon-Trusk P, Pry K, Velculescu V, Cristofanilli M, Bacus SS. Abstract 3887: Genomic analysis identifies drug targetable pathways and predicts immune infiltration in inflammatory breast cancer tumors Cancer Research. 75: 3887-3887. DOI: 10.1158/1538-7445.Am2015-3887 |
0.451 |
|
2014 |
Jones S, Stransky N, McCord CL, Cerami E, Lagowski J, Kelly D, Angiuoli SV, Sausen M, Kann L, Shukla M, Makar R, Wood LD, Diaz LA, Lengauer C, Velculescu VE. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nature Communications. 5: 5006. PMID 25233892 DOI: 10.1038/ncomms6006 |
0.356 |
|
2014 |
Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discovery. 4: 650-61. PMID 24801577 DOI: 10.1158/2159-8290.Cd-13-1014 |
0.422 |
|
2014 |
Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, ... Velculescu VE, et al. Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics : Official Journal of the Dna Methylation Society. 9: 1031-46. PMID 24786473 DOI: 10.4161/Epi.29025 |
0.449 |
|
2014 |
Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, López-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Calles A, Diaz LA, Velculescu VE, et al. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2476-84. PMID 24634382 DOI: 10.1158/1078-0432.Ccr-13-3047 |
0.379 |
|
2014 |
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, ... ... Velculescu VE, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine. 6: 224ra24. PMID 24553385 DOI: 10.1126/Scitranslmed.3007094 |
0.768 |
|
2014 |
Guerrero-Preston R, Michailidi C, Marchionni L, Pickering C, Frederick M, Myers J, Yegnasubramanian S, Hadar T, Noordhuis M, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu V, et al. Abstract 2482: Key tumor suppressor genes inactivated by promoter methylation and somatic mutations in head and neck cancer Cancer Research. 74: 2482-2482. DOI: 10.1158/1538-7445.Am2014-2482 |
0.566 |
|
2014 |
Moran DM, Rao K, Bacon-Trusk P, Pry K, Weigman V, Velculescu V, Cristofanilli M, Bacus S. 218 Genomic analysis identifies novel drivers and targetable pathways in inflammatory breast cancer patient samples European Journal of Cancer. 50: 74. DOI: 10.1016/S0959-8049(14)70344-2 |
0.442 |
|
2013 |
Diaz LA, Sausen M, Fisher GA, Velculescu VE. Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Oncotarget. 4: 1856-7. PMID 24196513 |
0.325 |
|
2013 |
Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, ... ... Velculescu VE, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genetics. 45: 1470-3. PMID 24185509 DOI: 10.1038/Ng.2813 |
0.363 |
|
2013 |
Leary RJ, Sausen M, Diaz LA, Velculescu VE. Cancer detection using whole-genome sequencing of cell free DNA. Oncotarget. 4: 1119-20. PMID 23912395 DOI: 10.18632/Oncotarget.1183 |
0.789 |
|
2013 |
Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, ... ... Velculescu VE, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discovery. 3: 658-73. PMID 23729478 DOI: 10.1158/2159-8290.CD-12-0558 |
0.305 |
|
2013 |
Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Molecular Cancer Therapeutics. 12: 1002-15. PMID 23729402 DOI: 10.1158/1535-7163.Mct-12-0813 |
0.396 |
|
2013 |
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science (New York, N.Y.). 339: 1546-58. PMID 23539594 DOI: 10.1126/Science.1235122 |
0.546 |
|
2013 |
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, ... ... Velculescu VE, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 110: 6021-6. PMID 23530248 DOI: 10.1093/Neuonc/Nou206.18 |
0.367 |
|
2013 |
Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, ... ... Velculescu VE, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. The Journal of Clinical Endocrinology and Metabolism. 98: E364-9. PMID 23264394 DOI: 10.1210/Jc.2012-2703 |
0.733 |
|
2013 |
Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, Hogarty MD. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genetics. 45: 12-7. PMID 23202128 DOI: 10.1038/Ng.2493 |
0.759 |
|
2013 |
Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, López-Ríos F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Diaz LA, Valencia A, Velculescu VE, et al. Integrated genomics and avatar mouse models for personalized cancer treatment. Journal of Clinical Oncology. 31: 2511-2511. DOI: 10.1200/Jco.2013.31.15_Suppl.2511 |
0.436 |
|
2013 |
Barrett MT, Lenkiewicz E, Lisa E, Perez-Mancera P, Tuveson D, Aust D, Pilarsky C, Aziz M, Posner R, Ramanathan R, Velculescu V, Kramer A, Drebin J, Hoff DDV. Abstract 798: Clonal analysis and clinical translation of pancreatic adenocarcinoma genomes. Cancer Research. 73: 798-798. DOI: 10.1158/1538-7445.Am2013-798 |
0.562 |
|
2013 |
Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, López-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Diaz LA, Valencia A, Velculescu VE, et al. Abstract 2205: Integrated next generation sequencing and patient-derived xenografts to personalized cancer treatment. Cancer Research. 73: 2205-2205. DOI: 10.1158/1538-7445.Am2013-2205 |
0.46 |
|
2012 |
Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA, Velculescu VE. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Science Translational Medicine. 4: 162ra154. PMID 23197571 DOI: 10.1126/Scitranslmed.3004742 |
0.774 |
|
2012 |
Yachida S, White CM, Naito Y, Zhong Y, Brosnan JA, Macgregor-Das AM, Morgan RA, Saunders T, Laheru DA, Herman JM, Hruban RH, Klein AP, Jones S, Velculescu V, Wolfgang CL, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6339-47. PMID 22991414 DOI: 10.1158/1078-0432.Ccr-12-1215 |
0.439 |
|
2012 |
Kim MS, Kuppireddy SV, Sakamuri S, Singal M, Getnet D, Harsha HC, Goel R, Balakrishnan L, Jacob HK, Kashyap MK, Tankala SG, Maitra A, Iacobuzio-Donahue CA, Jaffee E, Goggins MG, ... Velculescu VE, et al. Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). Journal of Proteome Research. 11: 5556-63. PMID 22985314 DOI: 10.1021/Pr300483R |
0.328 |
|
2012 |
Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL, Hruban RH. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4257-65. PMID 22896692 DOI: 10.1158/1078-0432.CCR-12-0315 |
0.472 |
|
2012 |
Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, Cheng Y, Twaddell WS, Latt NL, Shin EJ, Wang LD, Wang L, Yang W, Velculescu VE, Vogelstein B, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discovery. 2: 899-905. PMID 22877736 DOI: 10.1158/2159-8290.Cd-12-0189 |
0.366 |
|
2012 |
Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu VE, et al. ATM mutations in patients with hereditary pancreatic cancer Cancer Discovery. 2: 41-46. PMID 22585167 DOI: 10.1158/2159-8290.Cd-11-0194 |
0.427 |
|
2012 |
Willard MD, Lajiness ME, Wulur IH, Feng B, Swearingen ML, Uhlik MT, Kinzler KW, Velculescu VE, Sjöblom T, Markowitz SD, Powell SM, Vogelstein B, Barber TD. Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes. Molecular Cancer Research : McR. 10: 739-49. PMID 22516348 DOI: 10.1158/1541-7786.Mcr-11-0483 |
0.313 |
|
2012 |
Jones S, Li M, Williams Parsons D, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, ... ... Velculescu VE, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types Human Mutation. 33: 100-103. PMID 22009941 DOI: 10.1002/Humu.21633 |
0.424 |
|
2012 |
Garralda E, Calles A, López-Ríos F, Jones S, Kann LM, Angiuoli SV, Diaz LA, Velculescu VE, López-Casas PP, Sarno F, Martinez R, Gomez-Martin C, Conde E, Belda-Iniesta C, Valencia A, et al. Integrated next-generation sequencing and patient-derived xenografts to personalized cancer treatment. Journal of Clinical Oncology. 30: 3068-3068. DOI: 10.1200/Jco.2012.30.15_Suppl.3068 |
0.518 |
|
2012 |
Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy M, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu V, et al. Abstract 2628: Genome-wide sequencing identifiesATMas a pancreatic cancer susceptibility gene Cancer Research. 72: 2628-2628. DOI: 10.1158/1538-7445.Am2012-2628 |
0.504 |
|
2011 |
Diaz LA, Jiao Y, Shi C, Edil BH, de Wilde R, Klimstra DS, Maitra A, Tang LH, Blackford AL, Velculescu V, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. Exomic sequencing of pancreatic neuroendocrine tumors: Detection of alterations in chromatin remodeling and mTOR pathway genes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10501. PMID 28022366 DOI: 10.1200/Jco.2011.29.15_Suppl.10501 |
0.48 |
|
2011 |
Velculescu VE, Diaz LA. Understanding the enemy. Science Translational Medicine. 3: 98ps37. PMID 21885403 DOI: 10.1126/scitranslmed.3003001 |
0.32 |
|
2011 |
Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (New York, N.Y.). 333: 1453-5. PMID 21817013 DOI: 10.1126/Science.1210557 |
0.395 |
|
2011 |
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, ... ... Velculescu VE, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (New York, N.Y.). 333: 1154-7. PMID 21798897 DOI: 10.1126/Science.1206923 |
0.449 |
|
2011 |
Bessarabova M, Pustovalova O, Shi W, Serebriyskaya T, Ishkin A, Polyak K, Velculescu VE, Nikolskaya T, Nikolsky Y. Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. Cancer Research. 71: 3471-81. PMID 21398405 DOI: 10.1158/0008-5472.CAN-10-3038 |
0.412 |
|
2011 |
Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA, Vogelstein B, Kinzler KW, Hruban RH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (New York, N.Y.). 331: 1199-203. PMID 21252315 DOI: 10.1126/Science.1200609 |
0.411 |
|
2011 |
Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, ... ... Velculescu VE, et al. The genetic landscape of the childhood cancer medulloblastoma. Science (New York, N.Y.). 331: 435-9. PMID 21163964 DOI: 10.1126/Science.1198056 |
0.765 |
|
2011 |
Guerrero-Preston R, Agrawal N, Sidransky D, Li RJ, Westra WH, Koch WM, Califano JA, Vogelstein B, Velculescu VE, Papadopoulos N, Kinzler KW. Abstract PR3: Exome sequencing of head and neck squamous cell carcinoma reveals a higher frequency of mutations in TP53 among African Americans Cancer Epidemiology, Biomarkers & Prevention. 20. DOI: 10.1158/1055-9965.Disp-11-Pr3 |
0.426 |
|
2010 |
Boca SM, Kinzler KW, Velculescu VE, Vogelstein B, Parmigiani G. Patient-oriented gene set analysis for cancer mutation data Genome Biology. 11. PMID 21092299 DOI: 10.1186/Gb-2010-11-11-R112 |
0.398 |
|
2010 |
Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer Nature. 467: 1114-1117. PMID 20981102 DOI: 10.1038/Nature09515 |
0.739 |
|
2010 |
Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (New York, N.Y.). 330: 228-31. PMID 20826764 DOI: 10.1126/Science.1196333 |
0.459 |
|
2010 |
Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, ... ... Velculescu VE, et al. International network of cancer genome projects. Nature. 464: 993-8. PMID 20393554 DOI: 10.1038/Nature08987 |
0.419 |
|
2010 |
Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, Kinzler KW, Vogelstein B, Diaz LA, Velculescu VE. Development of personalized tumor biomarkers using massively parallel sequencing. Science Translational Medicine. 2: 20ra14. PMID 20371490 DOI: 10.1126/Scitranslmed.3000702 |
0.766 |
|
2010 |
He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, Velculescu VE, Diaz LA, Kinzler KW, Vogelstein B, Papadopoulos N. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature. 464: 610-4. PMID 20200521 DOI: 10.1038/Nature08802 |
0.363 |
|
2010 |
Zhang X, Li M, Ouillette P, Diaz L, Reis M, Velculescu V, Kinzler K, Malek S, Vogelstein B. Identification of Somatically Acquired Gene Mutations In the Kineome and Exome In CLL Blood. 116: 2410-2410. DOI: 10.1182/Blood.V116.21.2410.2410 |
0.504 |
|
2010 |
Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B, Papadopoulos N. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation (Proceedings of the National Academy of Sciences of the United States of America (2010) 107 (2598-2603) DOI: 10.1073/pnas.0914018107) Proceedings of the National Academy of Sciences of the United States of America. 107: 6551. DOI: 10.1073/Pnas.1002415107 |
0.33 |
|
2009 |
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (New York, N.Y.). 325: 1555-9. PMID 19661383 DOI: 10.1126/Science.1174229 |
0.321 |
|
2009 |
Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B, Karchin R. Cancer-specific high-throughput annotation of somatic mutations: Computational prediction of driver missense mutations Cancer Research. 69: 6660-6667. PMID 19654296 DOI: 10.1158/0008-5472.Can-09-1133 |
0.368 |
|
2009 |
Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JKV, Lowe JB, Wiesner GL, Parmigiani G, Barnholtz-Sloan J, Dawson DW, ... Velculescu VE, et al. Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers Proceedings of the National Academy of Sciences of the United States of America. 106: 12921-12925. PMID 19617566 DOI: 10.1073/Pnas.0901454106 |
0.446 |
|
2009 |
Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, ... ... Velculescu VE, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4674-9. PMID 19584151 DOI: 10.1158/1078-0432.Ccr-09-0227 |
0.764 |
|
2009 |
Duncan CG, Leary RJ, Lin JC, Cummins J, Di C, Schaefer CF, Wang TL, Riggins GJ, Edwards J, Bigner D, Kopelovich L, Vogelstein B, Kinzler KW, Velculescu VE, Yan H. Identification of microbial DNA in human cancer. Bmc Medical Genomics. 2: 22. PMID 19426505 DOI: 10.1186/1755-8794-2-22 |
0.731 |
|
2009 |
Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X, Parsons DW, Lin JCH, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Klein A, ... ... Velculescu VE, et al. Genetic mutations associated with Cigarette smoking in pancreatic cancer Cancer Research. 69: 3681-3688. PMID 19351817 DOI: 10.1158/0008-5472.Can-09-0015 |
0.715 |
|
2009 |
Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IeM. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. The American Journal of Pathology. 174: 1597-601. PMID 19349352 DOI: 10.2353/ajpath.2009.081000 |
0.384 |
|
2009 |
Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JCH, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene Science. 324: 217. PMID 19264984 DOI: 10.1126/Science.1171202 |
0.458 |
|
2009 |
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, ... Velculescu VE, et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine. 360: 765-73. PMID 19228619 DOI: 10.1056/Nejmoa0808710 |
0.391 |
|
2009 |
Parmigiani G, Boca S, Lin J, Kinzler KW, Velculescu V, Vogelstein B. Design and analysis issues in genome-wide somatic mutation studies of cancer Genomics. 93: 17-21. PMID 18692126 DOI: 10.1016/J.Ygeno.2008.07.005 |
0.471 |
|
2009 |
Konecny GE, Manivong K, Guorong E, Glas R, Dering J, Anderson L, Ginther C, Velculescu V, Calzone F, Slamon DJ. Abstract B232: Preclinical evaluation of AMG479 a fully human insulin‐like growth factor receptor‐1 (IGFR1) antibody in ovarian cancer cells Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B232 |
0.463 |
|
2008 |
Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjöblom T, Park BH, Parsons R, Willis J, Dawson D, Willson JK, Nikolskaya T, Nikolsky Y, ... ... Velculescu VE, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America. 105: 16224-9. PMID 18852474 DOI: 10.1073/Pnas.0808041105 |
0.772 |
|
2008 |
Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, ... ... Velculescu VE, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, N.Y.). 321: 1801-6. PMID 18772397 DOI: 10.1126/Science.1164368 |
0.771 |
|
2008 |
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, ... ... Velculescu VE, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (New York, N.Y.). 321: 1807-12. PMID 18772396 DOI: 10.1126/Science.1164382 |
0.778 |
|
2008 |
Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. Plos Medicine. 5: e114. PMID 18507500 DOI: 10.1371/Journal.Pmed.0050114 |
0.631 |
|
2008 |
Velculescu VE. Defining the blueprint of the cancer genome. Carcinogenesis. 29: 1087-91. PMID 18495658 DOI: 10.1093/carcin/bgn096 |
0.577 |
|
2008 |
Picelli S, Vandrovcova J, Jones S, Djureinovic T, Skoglund J, Zhou XL, Velculescu VE, Vogelstein B, Lindblom A. Genome-wide linkage scan for colorectal cancer susceptibility genes supports linkage to chromosome 3q Bmc Cancer. 8. PMID 18380902 DOI: 10.1186/1471-2407-8-87 |
0.305 |
|
2008 |
Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD. Comparative lesion sequencing provides insights into tumor evolution. Proceedings of the National Academy of Sciences of the United States of America. 105: 4283-8. PMID 18337506 DOI: 10.1073/Pnas.0712345105 |
0.475 |
|
2008 |
Barber TD, McManus K, Yuen KW, Reis M, Parmigiani G, Shen D, Barrett I, Nouhi Y, Spencer F, Markowitz S, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C, Hieter P. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America. 105: 3443-8. PMID 18299561 DOI: 10.1073/Pnas.0712384105 |
0.415 |
|
2008 |
Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer Cancer Research. 68: 889-892. PMID 18245491 DOI: 10.1158/0008-5472.Can-07-3095 |
0.539 |
|
2008 |
Velculescu V. Blueprint of the breast and colorectal cancer genomes European Journal of Cancer Supplements. 6: 123. DOI: 10.1016/S1359-6349(08)71644-6 |
0.346 |
|
2007 |
Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, Vogelstein B, Nowak MA. Genetic progression and the waiting time to cancer. Plos Computational Biology. 3: e225. PMID 17997597 DOI: 10.1371/Journal.Pcbi.0030225 |
0.445 |
|
2007 |
Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, ... ... Velculescu VE, et al. The genomic landscapes of human breast and colorectal cancers. Science (New York, N.Y.). 318: 1108-13. PMID 17932254 DOI: 10.1126/science.1145720 |
0.794 |
|
2007 |
Rago C, Huso DL, Diehl F, Karim B, Liu G, Papadopoulos N, Samuels Y, Velculescu VE, Vogelstein B, Kinzler KW, Diaz LA. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Research. 67: 9364-70. PMID 17909045 DOI: 10.1158/0008-5472.Can-07-0605 |
0.31 |
|
2007 |
Leary RJ, Cummins J, Wang TL, Velculescu VE. Digital karyotyping. Nature Protocols. 2: 1973-86. PMID 17703209 DOI: 10.1038/nprot.2007.276 |
0.707 |
|
2007 |
Lin J, Gan CM, Zhang X, Jones S, Sjöblom T, Wood LD, Parsons DW, Papadopoulos N, Kinzler KW, Vogelstein B, Parmigiani G, Velculescu VE. A multidimensional analysis of genes mutated in breast and colorectal cancers Genome Research. 17: 1304-1318. PMID 17693572 DOI: 10.1101/Gr.6431107 |
0.448 |
|
2007 |
Parmigiani G, Lin J, Boca SM, Sjöblom T, Jones S, Wood LD, Parsons DW, Barber T, Buckhaults P, Markowitz SD, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, ... Velculescu VE, et al. Response to comments on "The consensus coding sequences of human breast and colorectal cancers" Science. 317: 1500d. DOI: 10.1126/Science.1138773 |
0.307 |
|
2006 |
Bettegowda C, Huang X, Lin J, Cheong I, Kohli M, Szabo SA, Zhang X, Diaz LA, Velculescu VE, Parmigiani G, Kinzler KW, Vogelstein B, Zhou S. The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT Nature Biotechnology. 24: 1573-1580. PMID 17115055 DOI: 10.1038/Nbt1256 |
0.372 |
|
2006 |
Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, ... ... Velculescu VE, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biology & Therapy. 5: 928-32. PMID 16969076 DOI: 10.4161/Cbt.5.8.3251 |
0.362 |
|
2006 |
Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, ... ... Velculescu VE, et al. The consensus coding sequences of human breast and colorectal cancers Science. 314: 268-274. PMID 16959974 DOI: 10.1126/science.1133427 |
0.788 |
|
2006 |
Wood LD, Calhoun ES, Silliman N, Ptak J, Szabo S, Powell SM, Riggins GJ, Wang TL, Yan H, Gazdar A, Kern SE, Pennacchio L, Kinzler KW, Vogelstein B, Velculescu VE. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers Human Mutation.. 27: 1060-1061. PMID 16941478 DOI: 10.1002/Humu.9452 |
0.475 |
|
2006 |
Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih IeM. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biology & Therapy. 5: 779-85. PMID 16721043 |
0.439 |
|
2006 |
Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B, ... Velculescu VE, et al. The colorectal microRNAome. Proceedings of the National Academy of Sciences of the United States of America. 103: 3687-92. PMID 16505370 DOI: 10.1073/Pnas.0511155103 |
0.631 |
|
2005 |
Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Colorectal cancer: mutations in a signalling pathway. Nature. 436: 792. PMID 16094359 DOI: 10.1038/436792A |
0.337 |
|
2005 |
Hu M, Yao J, Cai L, Bachman KE, van den Brûle F, Velculescu V, Polyak K. Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genetics. 37: 899-905. PMID 16007089 DOI: 10.1038/Ng1596 |
0.412 |
|
2005 |
Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 7: 561-73. PMID 15950905 DOI: 10.1016/J.Ccr.2005.05.014 |
0.39 |
|
2005 |
Bardelli A, Velculescu VE. Mutational analysis of gene families in human cancer. Current Opinion in Genetics & Development. 15: 5-12. PMID 15661527 DOI: 10.1016/j.gde.2004.12.009 |
0.519 |
|
2004 |
Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas [6] New England Journal of Medicine. 351: 2883. PMID 15625347 DOI: 10.1056/Nejm200412303512724 |
0.342 |
|
2004 |
Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, ... ... Velculescu VE, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Research. 64: 8816-20. PMID 15604238 DOI: 10.1158/0008-5472.Can-04-1923 |
0.349 |
|
2004 |
Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle (Georgetown, Tex.). 3: 1221-4. PMID 15467468 DOI: 10.4161/cc.3.10.1164 |
0.426 |
|
2004 |
Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Research. 64: 5048-50. PMID 15289301 DOI: 10.1158/0008-5472.Can-04-1170 |
0.45 |
|
2004 |
Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biology & Therapy. 3: 772-5. PMID 15254419 DOI: 10.4161/Cbt.3.8.994 |
0.379 |
|
2004 |
Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, ... ... Velculescu VE, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (New York, N.Y.). 304: 1164-6. PMID 15155950 DOI: 10.1126/Science.1096096 |
0.428 |
|
2004 |
Wang Z, Cummins JM, Shen D, Cahill DP, Jallepalli PV, Wang TL, Parsons DW, Traverso G, Awad M, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz SD, Goldberg ML, ... ... Velculescu VE, et al. Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Research. 64: 2998-3001. PMID 15126332 DOI: 10.1158/0008-5472.Can-04-0587 |
0.415 |
|
2004 |
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science (New York, N.Y.). 304: 554. PMID 15016963 DOI: 10.1126/Science.1096502 |
0.336 |
|
2004 |
Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C. Inactivation of hCDC4 can cause chromosomal instability Nature. 428: 77-81. PMID 14999283 DOI: 10.1038/Nature02313 |
0.345 |
|
2004 |
Wang TL, Diaz LA, Romans K, Bardelli A, Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih IM, Iacobuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients Proceedings of the National Academy of Sciences of the United States of America. 101: 3089-3094. PMID 14970324 DOI: 10.1073/Pnas.0308716101 |
0.388 |
|
2003 |
Bardelli A, Saha S, Sager JA, Romans KE, Xin B, Markowitz SD, Lengauer C, Velculescu VE, Kinzler KW, Vogelstein B. PRL-3 Expression in Metastatic Cancers Clinical Cancer Research. 9: 5607-5615. PMID 14654542 |
0.327 |
|
2003 |
Buckhaults P, Zhang Z, Chen YC, Wang TL, St Croix B, Saha S, Bardelli A, Morin PJ, Polyak K, Hruban RH, Velculescu VE, Shih IeM. Identifying tumor origin using a gene expression-based classification map. Cancer Research. 63: 4144-9. PMID 12874019 |
0.31 |
|
2003 |
Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JKV, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine kinome in colorectal cancers Science. 300: 949. PMID 12738854 DOI: 10.1126/Science.1082596 |
0.371 |
|
2002 |
Wang TL, Maierhofer C, Speicher MR, Lengauer C, Vogelstein B, Kinzler KW, Velculescu VE. Digital karyotyping. Proceedings of the National Academy of Sciences of the United States of America. 99: 16156-61. PMID 12461184 DOI: 10.1073/Pnas.202610899 |
0.418 |
|
2002 |
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. RAF/RAS oncogenes and mismatch-repair status Nature. 418: 934. PMID 12198537 DOI: 10.1038/418934A |
0.369 |
|
2002 |
Wang TL, Rago C, Silliman N, Ptak J, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Prevalence of somatic alterations in the colorectal cancer cell genome. Proceedings of the National Academy of Sciences of the United States of America. 99: 3076-80. PMID 11867767 DOI: 10.1073/Pnas.261714699 |
0.537 |
|
2001 |
Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B. A phosphatase associated with metastasis of colorectal cancer. Science (New York, N.Y.). 294: 1343-6. PMID 11598267 DOI: 10.1126/Science.1065817 |
0.429 |
|
2001 |
Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G, Vogelstein B. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nature Genetics. 28: 184-7. PMID 11381269 DOI: 10.1038/88919 |
0.329 |
|
2000 |
St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes expressed in human tumor endothelium. Science (New York, N.Y.). 289: 1197-202. PMID 10947988 DOI: 10.1126/Science.289.5482.1197 |
0.412 |
|
1996 |
Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene Clinical Chemistry. 42: 858-868. PMID 8665676 DOI: 10.1093/Clinchem/42.6.858 |
0.364 |
|
Low-probability matches (unlikely to be authored by this person) |
2007 |
Peters BA, St Croix B, Sjöblom T, Cummins JM, Silliman N, Ptak J, Saha S, Kinzler KW, Hatzis C, Velculescu VE. Large-scale identification of novel transcripts in the human genome. Genome Research. 17: 287-92. PMID 17267814 DOI: 10.1101/Gr.5486607 |
0.296 |
|
2012 |
Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih IM. Low-grade serous carcinomas of the ovary contain very few point mutations Journal of Pathology. 226: 413-420. PMID 22102435 DOI: 10.1002/Path.3967 |
0.294 |
|
2006 |
Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, Velculescu VE, Shih IeM, Wang TL. Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biology & Therapy. 5: 630-4. PMID 16627982 |
0.293 |
|
2018 |
Leal A, Grieken NCTv, Phallen J, Palsgrove DN, Adleff V, Warmerdam F, Peet DLVd, Verheul HMW, Spronsen DJV, Riel JMV, Geenen M, Portielje JEA, Laarhoven HWMV, Jansen EP, Sikorska K, ... ... Velculescu VE, et al. Circulating tumor DNA dynamics in resectable gastric cancer. Journal of Clinical Oncology. 36: 4069-4069. DOI: 10.1200/Jco.2018.36.15_Suppl.4069 |
0.292 |
|
2018 |
Serrano C, Leal A, Phallen J, Marino-Enriquez A, Kuang Y, Triplett O, Morgan JA, Barysauskas C, Wagner AJ, Demetri GD, Velculescu VE, Paweletz C, Fletcher JA, George S. Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 36: 11510-11510. DOI: 10.1200/Jco.2018.36.15_Suppl.11510 |
0.29 |
|
2023 |
Sivapalan L, Iams WT, Belcaid Z, Scott SC, Niknafs N, Balan A, White JR, Kopparapu P, Cann C, Landon BV, Pereira G, Velculescu VE, Hann CL, Lovly CM, Anagnostou V. Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF14. PMID 37071497 DOI: 10.1158/1078-0432.CCR-22-2242 |
0.29 |
|
2011 |
Shih IeM, Panuganti PK, Kuo KT, Mao TL, Kuhn E, Jones S, Velculescu VE, Kurman RJ, Wang TL. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. The American Journal of Pathology. 178: 1442-7. PMID 21435433 DOI: 10.1016/J.Ajpath.2011.01.009 |
0.286 |
|
1993 |
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75: 817-25. PMID 8242752 DOI: 10.1016/0092-8674(93)90500-P |
0.281 |
|
2002 |
Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, Vogelstein B, Kinzler KW, Velculescu VE. Using the transcriptome to annotate the genome. Nature Biotechnology. 20: 508-12. PMID 11981567 DOI: 10.1038/Nbt0502-508 |
0.281 |
|
2010 |
Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B, Papadopoulos N. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proceedings of the National Academy of Sciences of the United States of America. 107: 2598-603. PMID 20133737 DOI: 10.1073/Pnas.0914018107 |
0.278 |
|
2019 |
Kelly RJ, Smith KN, Anagnostou V, Thompson E, Hales RK, Battafarano RJJ, Voong KR, Yang SC, Feliciano JL, Shin EJ, Hu C, El Asmar M, Chan HY, Velculescu VE, Sears C, et al. Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer. Journal of Clinical Oncology. 37: 142-142. DOI: 10.1200/JCO.2019.37.4_SUPPL.142 |
0.278 |
|
2018 |
Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, ... ... Velculescu VE, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget. 9: 28561-28571. PMID 29983880 DOI: 10.18632/Oncotarget.25564 |
0.276 |
|
2015 |
Husain H, Phallen J, Parpart-Li S, Murphy DM, Adleff V, Angiuoli SV, Jones S, Cohen EEW, Lippman SM, Diaz LA, Sausen M, Kurzrock R, Velculescu VE. A non-invasive liquid biopsy approach for therapeutic stratification of lung cancer patients. Journal of Clinical Oncology. 33: e19082-e19082. DOI: 10.1200/Jco.2015.33.15_Suppl.E19082 |
0.273 |
|
2014 |
Lipson EJ, Velculescu VE, Pritchard TS, Sausen M, Pardoll DM, Topalian SL, Diaz LA. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. Journal For Immunotherapy of Cancer. 2: 42. PMID 25516806 DOI: 10.1186/S40425-014-0042-0 |
0.272 |
|
2017 |
Husain H, Velculescu VE. Cancer DNA in the Circulation: The Liquid Biopsy. Jama. 318: 1272-1274. PMID 28973237 DOI: 10.1001/jama.2017.12131 |
0.272 |
|
2020 |
Schraa S, Van Rooijen K, Kruijssen D, Alarcón CR, Phallen J, Sausen M, Simmons J, Coupe V, Van Grevenstein H, Elias S, Verkooijen H, Bosch L, Van Den Broek D, Meijer G, Velculescu V, et al. 521TiP Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer according the trials within cohorts design: The MEDOCC-CrEATE trial Annals of Oncology. 31: S460. DOI: 10.1016/j.annonc.2020.08.631 |
0.27 |
|
2017 |
Vaz M, Hwang SY, Kagiampakis I, Phallen J, Patil A, O'Hagan HM, Murphy L, Zahnow CA, Gabrielson E, Velculescu VE, Easwaran HP, Baylin SB. Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. Cancer Cell. 32: 360-376.e6. PMID 28898697 DOI: 10.1016/J.Ccell.2017.08.006 |
0.27 |
|
2009 |
Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Research. 69: 9157-9. PMID 19996293 DOI: 10.1158/0008-5472.Can-09-2650 |
0.268 |
|
2019 |
Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, ... ... Velculescu VE, et al. Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. Journal For Immunotherapy of Cancer. 7: 40. PMID 30744692 DOI: 10.1186/S40425-018-0492-X |
0.266 |
|
2019 |
Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S. Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31471313 DOI: 10.1158/1078-0432.Ccr-19-2150 |
0.266 |
|
2018 |
Danilova L, Anagnostou V, Caushi JX, Sidhom JW, Guo H, Chan HY, Suri P, Tam AJ, Zhang J, El Asmar M, Marrone KA, Naidoo J, Brahmer JR, Forde PM, Baras AS, ... ... Velculescu VE, et al. The Mutation-Associated Neoantigen Functional Expansion of Specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. Cancer Immunology Research. PMID 29895573 DOI: 10.1158/2326-6066.Cir-18-0129 |
0.265 |
|
2009 |
Li M, Chen WD, Papadopoulos N, Goodman SN, Bjerregaard NC, Laurberg S, Levin B, Juhl H, Arber N, Moinova H, Durkee K, Schmidt K, He Y, Diehl F, Velculescu VE, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nature Biotechnology. 27: 858-63. PMID 19684580 DOI: 10.1038/nbt.1559 |
0.263 |
|
2011 |
Joshi AD, Parsons DW, Velculescu VE, Riggins GJ. Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. Molecular Cancer. 10: 17. PMID 21314958 DOI: 10.1186/1476-4598-10-17 |
0.26 |
|
2018 |
Asmar ME, Zhang J, Caushi J, Ji Z, Anagnostou V, Cottrell T, Chan HY, Suri P, Guo H, Marrone K, Naidoo J, Merghoub T, Chaft J, Hellmann M, Taube J, ... ... Velculescu V, et al. MA04.11 Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD-1 Blockade Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.348 |
0.258 |
|
2023 |
Ferrari AJ, Rawat P, Rendulich HS, Annapragada AV, Kinose Y, Zhang X, Devins K, Budina A, Scharpf RB, Mitchell MA, Tanyi JL, Morgan MA, Schwartz LE, Soong TR, Velculescu VE, et al. H2Bub1 loss is an early contributor to clear cell ovarian cancer progression. Jci Insight. 8. PMID 37345659 DOI: 10.1172/jci.insight.164995 |
0.258 |
|
2017 |
Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, Wenzel A, Hicks J, Ballew M, Stone M, Tran PT, Zahnow CA, Hellmann MD, Anagnostou V, Strissel PL, ... ... Velculescu VE, et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell. 171: 1284-1300.e21. PMID 29195073 DOI: 10.1016/J.Cell.2017.10.022 |
0.255 |
|
2018 |
Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone KA, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, ... ... Velculescu VE, et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Research. PMID 30541742 DOI: 10.1158/0008-5472.Can-18-1127 |
0.254 |
|
1995 |
Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science (New York, N.Y.). 270: 484-7. PMID 7570003 DOI: 10.1126/Science.270.5235.484 |
0.254 |
|
1999 |
Basrai MA, Velculescu VE, Kinzler KW, Hieter P. NORF5/HUG1 is a component of the MEC1-mediated checkpoint response to DNA damage and replication arrest in Saccharomyces cerevisiae Molecular and Cellular Biology. 19: 7041-7049. PMID 10490641 DOI: 10.1128/Mcb.19.10.7041 |
0.254 |
|
2007 |
Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, Polakiewicz RD, Kinzler KW, Vogelstein B, Velculescu VE, Wang ZJ. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proceedings of the National Academy of Sciences of the United States of America. 104: 4060-4. PMID 17360477 DOI: 10.1073/Pnas.0611665104 |
0.246 |
|
2006 |
Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 25: 6220-7. PMID 17028602 DOI: 10.1038/sj.onc.1209914 |
0.246 |
|
2019 |
Caushi J, Ji Z, Zhang J, Asmar ME, Anagnostou V, Cottrell T, Chan HY, Guo H, Merghoub T, Wolchok J, Naidoo J, Marrone K, Chaft J, Hellmann M, Gabrielson E, ... ... Velculescu V, et al. P2.04-24 Transcriptional Profiling of Neoantigen Specific T Cells in Resectable NSCLC Treated with Neoadjuvant Anti-PD-1 Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1529 |
0.243 |
|
2020 |
Anagnostou V, Niknafs N, Marrone K, Bruhm DC, White JR, Naidoo J, Hummelink K, Monkhorst K, Lalezari F, Lanis M, Rosner S, Reuss JE, Smith KN, Adleff V, Rodgers K, ... ... Velculescu VE, et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer Nature Cancer. 1: 99-111. DOI: 10.1038/s43018-019-0008-8 |
0.242 |
|
2020 |
Murray JC, Rhymee L, Marrone K, Naidoo J, Levy BP, Ferreira L, Rosner S, Lanis M, Hann CL, Feliciano JL, Lam VK, Ettinger DS, Illei PB, Wang C, Brahmer JR, ... ... Velculescu VE, et al. Comprehensive modeling of longitudinal circulating tumor DNA dynamics to predict clinical response to first-line immunotherapy and chemoimmunotherapy in advanced non-small cell lung cancer. Journal of Clinical Oncology. 38: 9525-9525. DOI: 10.1200/jco.2020.38.15_suppl.9525 |
0.242 |
|
2017 |
Smith K, Anagnostou V, Forde P, Brahmer J, Velculescu V, Pardoll D. OA20.02 Neoantigen Targeting in NSCLC Patients with Complete Response to Anti-PD-1 Immunotherapy Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.344 |
0.241 |
|
2023 |
Leal AIC, Mathios D, Jakubowski D, Johansen JS, Lau A, Wu T, Cristiano S, Medina JE, Phallen J, Bruhm DC, Carey J, Dracopoli NC, Bojesen SE, Scharpf RB, Velculescu VE, et al. Cell-free DNA fragmentomes in the diagnostic evaluation of patients with symptoms suggestive of lung cancer. Chest. PMID 37116747 DOI: 10.1016/j.chest.2023.04.033 |
0.24 |
|
2015 |
Parpart-Li S, Angiuoli SV, Chesnick B, Galens K, Jones S, Kadan M, Kann L, Lytle K, Murphy DM, Nesselbush M, Phallen J, Riley D, Shukla M, Zhang T, Husain H, ... Velculescu VE, et al. A method for comprehensive genomic analysis of cell-free DNA. Journal of Clinical Oncology. 33: e22070-e22070. DOI: 10.1200/JCO.2015.33.15_SUPPL.E22070 |
0.239 |
|
2005 |
Peters BA, Velculescu VE. Transcriptome PETs: a genome's best friends. Nature Methods. 2: 93-4. PMID 15782204 DOI: 10.1038/Nmeth0205-93 |
0.238 |
|
1997 |
Velculescu VE, Zhang L, Zhou W, Vogelstein J, Basrai MA, Bassett DE, Hieter P, Vogelstein B, Kinzler KW. Characterization of the yeast transcriptome Cell. 88: 243-251. PMID 9008165 DOI: 10.1016/S0092-8674(00)81845-0 |
0.237 |
|
2019 |
Zhang J, Ji Z, Caushi JX, El Asmar M, Anagnostou V, Cottrell TR, Chan HY, Suri P, Guo H, Merghoub T, Chaft JE, Reuss JE, Tam AJ, Blosser RL, Abu-Akeel M, ... ... Velculescu VE, et al. Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31754049 DOI: 10.1158/1078-0432.Ccr-19-2931 |
0.236 |
|
2019 |
Zhang J, Ji Z, Caushi J, Asmar ME, Anagnostou V, Cottrell T, Chan HY, Guo H, Merghoub T, Chaft J, Wolchok J, Reuss J, Marrone K, Naidoo J, Gabrielson E, ... ... Velculescu V, et al. MA11.10 Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 Blockade Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.590 |
0.236 |
|
2015 |
Murphy DM, Angiuoli SV, Chesnick B, Galens K, Jones S, Kadan M, Kann LM, Lytle K, Nesselbush M, Parpart-Li S, Phallen J, Riley D, Shukla M, Zhang T, Husain H, ... Velculescu VE, et al. A comprehensive noninvasive approach for the stratification of lung cancer patients for targeted therapies. Journal of Clinical Oncology. 33: e22086-e22086. DOI: 10.1200/JCO.2015.33.15_SUPPL.E22086 |
0.231 |
|
2012 |
Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. The predictive capacity of personal genome sequencing. Science Translational Medicine. 4: 133ra58. PMID 22472521 DOI: 10.1126/Scitranslmed.3003380 |
0.231 |
|
2022 |
Hwang M, Canzoniero JV, Rosner S, Zhang G, White JR, Belcaid Z, Cherry C, Balan A, Pereira G, Curry A, Niknafs N, Zhang J, Smith KN, Sivapalan L, Chaft JE, ... ... Velculescu VE, et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. Journal For Immunotherapy of Cancer. 10. PMID 35688557 DOI: 10.1136/jitc-2022-004688 |
0.227 |
|
2020 |
Lam V, Hales R, Feliciano J, Voong K, Shin E, Smith K, Anagnostou V, Velculescu V, Thompson E, Sears C, Pardoll D, Rodavia H, Schneider H, Hu C, Amjad A, et al. 1497TiP REACTION – a phase Ib pilot study of nivolumab or nivolumab in combination with relatlimab after targeted radiation in patients with advanced esophagogastric cancer Annals of Oncology. 31: S929. DOI: 10.1016/j.annonc.2020.08.2003 |
0.225 |
|
2020 |
Selvan ME, Zauderer MG, Rudin CM, Jones S, Mukherjee S, Offit K, Onel K, Rennert G, Velculescu VE, Lipkin SM, Klein RJ, Gümüş ZH. Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32866655 DOI: 10.1016/J.Jtho.2020.08.017 |
0.225 |
|
2023 |
Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, Rhymee L, Pereira G, Rao N, Weksler B, Bahary N, Phallen J, Leal A, Bartlett DL, Marrone KA, ... ... Velculescu VE, et al. Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37939140 DOI: 10.1158/1078-0432.CCR-23-1469 |
0.222 |
|
2014 |
Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, Konecny GE. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2947-58. PMID 24727326 DOI: 10.1158/1078-0432.CCR-13-3448 |
0.218 |
|
2017 |
Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, ... ... Velculescu VE, et al. Abstract NG01: Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ng01 |
0.217 |
|
2023 |
Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, Rhymee L, Pereira G, Rao N, Phallen J, Leal A, Bartlett DL, Marrone KA, Naidoo J, Levy B, ... ... Velculescu VE, et al. Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer. Biorxiv : the Preprint Server For Biology. PMID 37425893 DOI: 10.1101/2023.06.23.546338 |
0.217 |
|
2012 |
Vogelstein B, Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Velculescu VE. Response to comments on "The predictive capacity of personal genome sequencing" Science Translational Medicine. 4. DOI: 10.1126/Scitranslmed.3004246 |
0.216 |
|
2015 |
O'Hara MH, Gallagher M, Teitelbaum UR, Giantonio BJ, Damjanov N, Loaiza-Bonilla A, Amaravadi RK, Heitjan DF, Vasilevskaya I, Hoff DDV, Ramanathan RK, Laheru D, Jesus-Acosta AD, Velculescu VE, O'Dwyer PJ. Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E15213 |
0.216 |
|
2020 |
Reuss JE, Anagnostou V, Cottrell TR, Smith KN, Verde F, Zahurak M, Lanis M, Murray JC, Chan HY, McCarthy C, Wang D, White JR, Yang S, Battafarano R, Broderick S, ... ... Velculescu VE, et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. Journal For Immunotherapy of Cancer. 8. PMID 32929052 DOI: 10.1136/jitc-2020-001282 |
0.215 |
|
2007 |
Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM. The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations Science. 318: 1744-1748. PMID 18079394 DOI: 10.1126/Science.1150799 |
0.208 |
|
2019 |
Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, ... ... Velculescu VE, et al. Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (Journal for Immuno Therapy of Cancer (2019) 7 (40) DOI: 10.1186/s40425-018-0492-x) Journal For Immunotherapy of Cancer. 7: 7. PMID 30841906 DOI: 10.1186/S40425_019_0547_7 |
0.208 |
|
2011 |
Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1591-602. PMID 21278246 DOI: 10.1158/1078-0432.CCR-10-2307 |
0.207 |
|
2018 |
Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, Meijer GA, Rollins BJ, Sawyers CL, Schultz N, Shaw KRM, Velculescu VE, Levy MA. American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives. Jco Clinical Cancer Informatics. 1-14. PMID 30652542 DOI: 10.1200/CCI.17.00083 |
0.204 |
|
2019 |
Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, Sampath D, Mills GB, Brugge JS. Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness. Molecular Cancer Therapeutics. PMID 30679390 DOI: 10.1158/1535-7163.Mct-18-0413 |
0.203 |
|
2018 |
Cottrell TR, Stein JE, Chaft JE, Thompson ED, Rekhtman N, Anagnostou V, Smith KN, Duffield AS, Anders RA, Isbell JM, Jones DR, Cuda JD, Battafarano R, Yang SC, Illei PB, ... ... Velculescu VE, et al. Abstract LB-154: Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma (NSCLC): A proposal for quantitative immune-related pathologic response criteria (irPRC) Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-154 |
0.199 |
|
2022 |
Mathios D, Bach PB, Phallen JA, Scharpf RB, Velculescu VE. Reply to: Limitations of molecular testing in combination with computerized tomographic for lung cancer screening. Nature Communications. 13: 3892. PMID 35803904 DOI: 10.1038/s41467-022-31420-2 |
0.199 |
|
2008 |
He Y, Vogelstein B, Velculescu VE, Papadopoulos N, Kinzler KW. The antisense transcriptomes of human cells. Science (New York, N.Y.). 322: 1855-7. PMID 19056939 DOI: 10.1126/Science.1163853 |
0.197 |
|
2019 |
Shao XM, Bhattacharya R, Huang J, Sivakumar IKA, Tokheim C, Zheng L, Hirsch D, Kaminow B, Omdahl A, Bonsack M, Riemer AB, Velculescu VE, Anagnostou V, Pagel KA, Karchin R. High-throughput prediction of MHC class I and class II neoantigens with MHCnuggets. Cancer Immunology Research. PMID 31871119 DOI: 10.1158/2326-6066.Cir-19-0464 |
0.195 |
|
2018 |
Kelly RJ, Hales RK, Battafarano RJ, Voong KR, Yang SC, Shin EJ, Hu C, Anagnostou V, Velculescu VE, Feliciano JL, Thompson E, Smith KN, Sears C, Pardoll DM, Rowe V, et al. Induction nivolumab or nivolumab/ipilimumab prior to concurrent chemoradiation plus nivolumab in patients with operable stage II/III esophageal/gastroesophageal junction cancer. Journal of Clinical Oncology. 36: TPS4140-TPS4140. DOI: 10.1200/JCO.2018.36.15_SUPPL.TPS4140 |
0.194 |
|
2000 |
Velculescu VE, Vogelstein B, Kinzler KW. Analysing uncharted transcriptomes with SAGE. Trends in Genetics : Tig. 16: 423-5. PMID 11050322 DOI: 10.1016/S0168-9525(00)02114-4 |
0.192 |
|
2021 |
Niknafs N, Forde P, Lanis M, Belcaid Z, Smith K, Sun Z, Balan A, White J, Cherry C, Shivakumar A, Shao X, Kindler H, Purcell T, Santana-Davila R, Dudek A, ... ... Velculescu V, et al. OA12.01 Genomic and Immune Cell Landscape of Response to Chemo-Immunotherapy in Malignant Pleural Mesothelioma Journal of Thoracic Oncology. 16: S867-S868. DOI: 10.1016/j.jtho.2021.08.072 |
0.185 |
|
2002 |
Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW. Allelic variation in human gene expression. Science (New York, N.Y.). 297: 1143. PMID 12183620 DOI: 10.1126/science.1072545 |
0.178 |
|
2023 |
Kim ES, Scharpf RB, Garcia-Closas M, Visvanathan K, Velculescu VE, Chatterjee N. Potential utility of risk stratification for multicancer screening with liquid biopsy tests. Npj Precision Oncology. 7: 39. PMID 37087533 DOI: 10.1038/s41698-023-00377-w |
0.166 |
|
2018 |
Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, ... ... Velculescu VE, et al. Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Criteria (irPRC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29982279 DOI: 10.1093/Annonc/Mdy218 |
0.163 |
|
1998 |
Bertelsen AH, Velculescu VE. High-throughput gene expression analysis using SAGE Drug Discovery Today. 3: 152-159. DOI: 10.1016/S1359-6446(97)01160-4 |
0.16 |
|
2011 |
Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, Pawlik TM, Daniel HD, Kannangai R, Offerhaus GJ, Velculescu VE, Wang L, Zhou S, Vogelstein B, Hruban RH, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature Genetics. 43: 828-9. PMID 21822264 DOI: 10.1038/Ng.903 |
0.16 |
|
2021 |
Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, Mog BJ, Hou W, Justesen S, Blosser R, Tam A, Anagnostou V, Cottrell TR, Guo H, Chan HY, ... ... Velculescu VE, et al. Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. PMID 34608287 DOI: 10.1038/s41586-021-03893-6 |
0.159 |
|
2005 |
Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, McLendon RE, Bigner DD, Yan H. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Research. 65: 919-24. PMID 15705891 |
0.157 |
|
2020 |
Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenberg RA, Schwartz L, Johnson N, ... ... Velculescu VE, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nature Communications. 11: 3726. PMID 32709856 DOI: 10.1038/s41467-020-17127-2 |
0.155 |
|
2007 |
Velculescu VE, Kinzler KW. Gene expression analysis goes digital. Nature Biotechnology. 25: 878-80. PMID 17687366 DOI: 10.1038/Nbt0807-878 |
0.154 |
|
2016 |
Forde P, Smith K, Chaft J, Hellmann M, Merghoub T, Wolchok J, Yang S, Battafarano R, Gabrielson E, Georgiades C, Verde F, Rosner G, Naidoo J, Cottrell T, Taube J, ... ... Velculescu V, et al. NSCLC, early stage Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer Annals of Oncology. 27: vi576. DOI: 10.1093/Annonc/Mdw435.38 |
0.152 |
|
2021 |
Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, Mog BJ, Hou W, Justesen S, Blosser R, Tam A, Anagnostou V, Cottrell TR, Guo H, Chan HY, ... ... Velculescu VE, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. PMID 34290408 DOI: 10.1038/s41586-021-03752-4 |
0.151 |
|
2016 |
Forde PM, Smith K, Chaft JE, Hellmann MD, Merghoub T, Wolchok JD, Yang SC, Battafarano RJ, Gabrielson E, Georgiades C, Verde F, Rosner GL, Anagnostou V, Velculescu VE, Topalian SL, et al. Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. Journal of Clinical Oncology. 34: e20005-e20005. DOI: 10.1200/Jco.2016.34.15_Suppl.E20005 |
0.148 |
|
2017 |
Nesselbush M, Angiuoli S, Diaz LA, Georgiadis A, Glynn S, Jones S, Keefer L, LoVerso P, Murphy D, Parpart-Li S, Riley D, Sengamalay N, Shukla M, Simmons J, Talati S, ... ... Velculescu VE, et al. Abstract 4954: Clinical validation of a cell-free DNA liquid biopsy approach for noninvasive molecular profiling Cancer Research. 77: 4954-4954. DOI: 10.1158/1538-7445.Am2017-4954 |
0.146 |
|
1999 |
Velculescu VE. Essay: Amersham Pharmacia Biotech & Science prize. Tantalizing transcriptomes--SAGE and its use in global gene expression analysis. Science (New York, N.Y.). 286: 1491-2. PMID 10610550 DOI: 10.1126/SCIENCE.286.5444.1491 |
0.144 |
|
1999 |
Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, et al. Analysis of human transcriptomes. Nature Genetics. 23: 387-8. PMID 10581018 DOI: 10.1038/70487 |
0.14 |
|
2020 |
Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, ... ... Velculescu VE, et al. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. PMID 32916126 DOI: 10.1016/J.Ccell.2020.08.005 |
0.133 |
|
2019 |
Rosner S, Forde PM, Naidoo J, Marrone K, Reuss JE, Feliciano JL, Levy BP, Hann CL, Velculescu VE, Brahmer JR, Anagnostou V. Early shifts in immune cell subsets to predict response to immune checkpoint blockade in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 37: 105-105. DOI: 10.1200/JCO.2019.37.8_SUPPL.105 |
0.128 |
|
2018 |
Marrone K, Zhang J, Feliciano JL, Forde PM, Hann CL, Kelly RJ, Ettinger DS, Turner M, Rowe V, Bonerigo S, Smith KN, Anagnostou V, Velculescu VE, Brahmer JR, Naidoo J. Immune checkpoint inhibition in elderly non-small cell lung cancer patients. Journal of Clinical Oncology. 36: 137-137. DOI: 10.1200/JCO.2018.36.5_SUPPL.137 |
0.125 |
|
2013 |
Bucur O, Almasan A, Nikolajczyk BS, Nicolson GL, Lawler J, Velculescu VE, Draghici S, Leabu M, Avram D, Bucur I, Calautti E, Calin GA, Chauhan SC, Ciubotaru M, Constantinescu SN, et al. Discoveries: an innovative platform for publishing cutting-edge research discoveries in medicine, biology and chemistry. Discoveries (Craiova, Romania). 1: e1. PMID 32309535 DOI: 10.15190/d.2013.1 |
0.122 |
|
2024 |
Anagnostou V, Velculescu VE. Pushing the Boundaries of Liquid Biopsies for Early Precision Intervention. Cancer Discovery. 14: 615-619. PMID 38571422 DOI: 10.1158/2159-8290.CD-24-0037 |
0.12 |
|
2008 |
Velculescu V. The intersection of basic science and health policy: a conversation with Victor Velculescu. Interview by Barbara J. Culliton. Health Affairs (Project Hope). 27: w27-33. PMID 18042563 DOI: 10.1377/hlthaff.27.1.w27 |
0.115 |
|
2019 |
Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, ... ... Velculescu VE, et al. Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. Journal For Immunotherapy of Cancer. 7: 63. PMID 30841906 DOI: 10.1186/S40425-019-0547-7 |
0.114 |
|
2020 |
Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, ... ... Velculescu VE, et al. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. PMID 33306984 DOI: 10.1016/j.ccell.2020.11.015 |
0.074 |
|
2017 |
Cerami E, Baras AS, Guinney J, Lepisto E, Pugh TJ, Schultz N, Stricker T, Sweeney SM, Veer LJv, Meijer GA, Andre F, Velculescu VE, Shaw KR, Levy MA, Bedard PL, et al. Abstract LB-102: Landscape analysis of the initial data release from AACR Project GENIE Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-102 |
0.044 |
|
2015 |
Velculescu V, Bender E. Q&A: Victor Velculescu. Out for blood. Nature. 521: S9. PMID 25970458 DOI: 10.1038/521S9a |
0.022 |
|
1999 |
Velculescu V, Velji AM. Capnocytophaga canimorsus(DF-2) Infection: A Continuing Challenge for Clinicians and Microbiologists* Microbial Ecology in Health & Disease. 10. DOI: 10.3402/MEHD.V10I3-4.7874 |
0.01 |
|
Hide low-probability matches. |